Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Bleeding disorder testing industry 360º synopsis, 2018 – 2032
2.2 Business trends
2.3 Regional trends
2.4 Product type trends
2.5 Indication trends
2.6 End-use trends
Chapter 3 Bleeding Disorder Testing Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of blood disorders
3.2.1.2 Technological advancements
3.2.1.3 Supportive awareness initiatives
3.2.1.4 Recent product approvals
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of skilled professionals
3.3 Growth potential analysis
3.3.1 By product
3.3.2 By indication
3.3.3 By end use
3.4 COVID- 19 impact analysis
3.5 Pricing analysis, 2022, by region
3.5.1 North America
3.5.1.1 U.S.
3.5.1.2 Canada
3.5.2 Europe
.3.5.2.1. Germany
3.5.2.2 UK
3.5.2.3 France
3.5.2.4 Spain
3.5.2.5 Italy
3.5.2.6 Poland
3.5.2.7 Switzerland
3.5.2.8 The Netherlands
3.5.3 Asia Pacific
3.5.3.1 Japan
3.5.3.2 China
3.5.3.3 India
3.5.3.4 Australia
3.5.3.5 South Korea
3.5.3.6 Indonesia
3.5.3.7 Philippines
3.5.3.8 Vietnam
3.5.4 Latin America
3.5.4.1 Brazil
3.5.4.2 Mexico
3.5.4.3 Argentina
3.5.4.4 Columbia
3.5.4.5 Chile
3.5.4.6 Peru
3.5.5 MEA
3.5.5.1 South Africa
3.5.5.2 Saudi Arabia
3.5.5.3 UAE
3.5.5.4 Israel
3.5.5.5 Egypt
3.5.5.6 Turkey
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Reimbursement scenario
3.7.1 U.S.
3.8 Technological advancements
3.9 Gap analysis
3.10 Porter's analysis
3.11 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Vendor matrix analysis
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Bleeding Disorder Testing Market Size and Forecast, By Product Type (USD Million & Units)
5.1 Key trends, by product type
5.2 Reagents & consumbales
5.3 Instruments
Chapter 6 Bleeding Disorder Testing Market Size and Forecast, By Indication (USD Million)
6.1 Key trends, by indication
6.2 Hemophilia A
6.3 Hemophilia B
6.4 Von Willebrand Disease
6.5 Idiopathic Thrombocytopenic Purpura
6.6 Others
Chapter 7 Bleeding Disorder Testing Market Size and Forecast, By End-use (USD Million)
7.1 Key trends, by end-use
7.2 Hospitals & clinics
7.3 Diagnostic centers
7.4 Others
Chapter 8 Bleeding Disorder Testing Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Switzerland
8.3.8 The Netherlands
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Indonesia
8.4.7 Philippines
8.4.8 Vietnam
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Chile
8.5.6 Peru
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Israel
8.6.5 Egypt
8.6.6 Turkey
Chapter 9 Company Profiles
9.1 Siemens Healthineers
9.2 F Hoffmann-La Roche Ltd
9.3 Abbott Laboratories
9.4 Bio-Rad Laboratories, Inc
9.5 Thermo Fisher Scientific Inc
9.6 Grifols SA
9.7 Sysmex Corporation
9.8 Werfen
9.9 Cephied (Danaher Corporation)
9.10 HORIBA Ltd
9.11 Hyphen Biomed
9.12 Precision Biologics Inc.
9.13 Atlas Medical GmbH
9.14 PreventionGenetics (Exact Sciences Corp)
9.15 Blueprint Genetics Oy
9.16 American Biochemical & Pharmaceuticals Limited
9.17 DiaPharma
